Detection of Yeast Fungi with Artificial Intelligence Supported Impedimetric Odor Biosensor

The specific problem we are addressing is the challenge of diagnosing and managing fungal infections, particularly in populations with compromised immune systems, such as HIV/AIDS patients, organ transplant recipients, and individuals undergoing long-term steroid or chemotherapy treatment. Fungal infections caused by species like Candida and Aspergillus pose significant health risks and can lead to serious complications if not promptly diagnosed and treated.

Globally, fungal infections are recognized as a major health concern affecting millions of individuals, especially in developing countries where access to healthcare resources may be limited (A. K. Gupta, Versteeg & Shear, 2017). The incidence of fungal infections is notably high in immunocompromised populations.

Immunocompromised individuals, including HIV/AIDS patients, cancer patients undergoing chemotherapy, and transplant recipients, are particularly susceptible to fungal infections due to their weakened immune systems (Garber, 2001; Gupta et al., 2017). In these vulnerable populations, fungal infections can become systemic and life-threatening if not managed effectively.

The emergence of antifungal resistance further complicates the treatment of fungal infections, limiting available therapeutic options and contributing to treatment failures (Brown et al., 2012).

Diagnostic challenges also significantly impact the management of fungal infections. Traditional diagnostic methods, such as microscopy, culture, and molecular testing, often have limitations including time-consuming processes and potential uncertainties in results, particularly in immunocompromised patients (Lass-Flörl, 2017; Perfect, 2017).

Our solution aims to address these challenges by developing a rapid, accurate, and accessible diagnostic method for fungal infections. By leveraging advanced technologies like molecular biology, genetics, and artificial intelligence (AI), we intend to enhance diagnostic precision and enable timely interventions, ultimately improving health outcomes for individuals affected by fungal infections globally.

The impact of our solution extends to reducing morbidity and mortality associated with fungal infections, particularly in vulnerable communities with limited access to healthcare resources. By providing a reliable and efficient diagnostic tool, we aim to empower healthcare providers to initiate appropriate treatments promptly, leading to improved patient outcomes and overall public health.

Through strategic partnerships and collaborations with healthcare institutions and stakeholders, we seek to implement and scale our diagnostic solution to reach underserved communities most affected by fungal infections. By addressing the specific challenges related to fungal infection diagnosis, our project contributes to advancing global health equity and promoting better health outcomes for vulnerable populations worldwide.

Our solution is an innovative diagnostic biosensor designed to rapidly and accurately detect fungal infections, particularly in immunocompromised individuals. This biosensor utilizes a combination of molecular biology, genetics, chemistry, physics, electronics and artificial intelligence (AI) to revolutionize the process of diagnosing fungal infections.

At its core, our impedimetric smell biosensor leverages molecular techniques to detect specific DNA markers or genetic signatures associated with various fungal species, such as Candida and Aspergillus. This allows for highly sensitive and specific identification of the causative fungal agent in patient samples.

The workflow of our solution involves collecting a sample (e.g., blood, tissue, or bodily fluid) from the patient suspected of having a fungal infection. This sample is then processed using our molecular diagnostic platform, where DNA extraction and amplification techniques are employed to detect fungal genetic material.

The key technology utilized in our solution is polymerase chain reaction (PCR), a molecular biology technique that amplifies targeted DNA sequences, making them easier to detect. PCR is coupled with genetic probes or primers specifically designed to recognize fungal DNA, enabling selective identification of fungal pathogens.

Additionally, our solution incorporates AI algorithms for data analysis and interpretation. AI algorithms are trained to recognize patterns within the genetic data, allowing for automated identification and classification of fungal species based on their unique genetic signatures. This integration of AI enhances the accuracy and efficiency of fungal infection diagnosis.

Overall, our solution offers a streamlined and efficient approach to diagnosing fungal infections, providing clinicians with rapid and reliable results to guide timely and targeted treatment decisions. By combining molecular biology, genetics, and AI technology, our diagnostic tool represents a cutting-edge advancement in fungal infection diagnostics, ultimately improving patient outcomes and contributing to better healthcare delivery globally.

Our solution targets vulnerable and underserved populations, particularly those with low socioeconomic status and increased health risks due to immunocompromised conditions. This includes individuals such as HIV/AIDS patients, organ transplant recipients, cancer patients undergoing chemotherapy, and others with weakened immune systems who face heightened susceptibility to fungal infections.

These populations are often underserved and face significant barriers in accessing timely and accurate diagnosis and treatment of fungal infections. Current diagnostic methods are often labor-intensive, slow, and prone to errors, leading to delays in appropriate care and suboptimal health outcomes. In resource-limited settings, healthcare infrastructure may be inadequate, further exacerbating disparities in health services.

Our solution directly impacts their lives by introducing a novel diagnostic tool based on molecular biology and artificial intelligence (AI) technology. By leveraging these advanced technologies, our solution offers a rapid, accurate, and user-friendly platform that can be deployed in diverse healthcare settings, including resource-constrained environments.

The solution addresses the specific needs of vulnerable populations by:

1.  By providing a cost-effective and scalable diagnostic tool, our solution enhances access to timely and accurate diagnosis of fungal infections, particularly in under-resourced communities where traditional diagnostic methods may be unavailable or unaffordable.

2. Our solution contributes to advancing health equity by empowering healthcare providers with innovative technology that enables personalized and targeted treatment strategies for immunocompromised individuals. This helps reduce disparities in health outcomes and ensures equitable access to quality care.

3. The rapid and accurate diagnosis offered by our solution facilitates early intervention and appropriate treatment initiation, which is crucial for preventing disease progression and reducing complications among vulnerable populations.

4. By leveraging AI-driven data analysis, our solution enhances the capacity of healthcare systems in resource-constrained settings, enabling more efficient allocation of resources and improving overall healthcare delivery.

In summary, our solution serves to bridge the gap in access to quality healthcare for vulnerable and underserved populations affected by fungal infections. By harnessing the power of technology and innovation, we aim to empower communities and healthcare providers with tools that promote health equity, improve health outcomes, and ultimately contribute to achieving universal access to comprehensive health services for all.

Our team is uniquely positioned to deliver this solution due to our direct experience and close proximity to underserved communities, particularly in Turkey, where millions of refugees and immigrants lack access to comprehensive healthcare services. As a team based in Turkey, we understand the challenges faced by vulnerable populations firsthand and are committed to developing innovative and cost-effective solutions to address their healthcare needs.

Our team have personal connections and interactions with refugees, immigrants, and underserved populations on a daily basis. We witness the barriers they encounter in accessing healthcare, including lack of health records, insurance, and financial resources. This firsthand experience motivates us to design a solution that is not only technically feasible but also culturally sensitive and accessible to those who need it most.

Our solution's design and implementation are meaningfully guided by input from the communities we serve. We engage directly with refugee and immigrant communities through community-based organizations, local clinics, and grassroots initiatives. Through workshops, focus groups, and interviews, we listen to their experiences, needs, and preferences regarding healthcare services.

Key elements of community involvement in our solution development include:

1. Needs Assessment: We aim to conduct comprehensive needs assessments within refugee and immigrant communities to identify specific health challenges and priorities. 

2. Co-design: We would like to co-design by involving community members in brainstorming and decision-making processes. Together, we can collaboratively develop the solution to ensure it meets the unique needs and preferences of the target population.

3. Cultural Sensitivity: We prioritize cultural sensitivity in our solution design. By understanding the diverse cultural backgrounds and languages of the communities we serve, we would like to tailor our solution to be inclusive and respectful of cultural norms and practices.

4. Accessibility and Affordability: Community input guides us in making the solution accessible and affordable. We explore alternative healthcare delivery models that leverage technology to reduce costs and improve access for underserved populations.

Overall, our team's close proximity to underserved communities in Turkey, coupled with our commitment to community engagement and co-design, ensures that our solution is relevant, impactful, and empowering for those who need it most. By partnering with and listening to the voices of refugees and immigrants, we aim to develop a healthcare solution that promotes health equity and improves the quality of life for vulnerable populations in Turkey and beyond.

We have selected the prototype stage for our biosensor solution because we have successfully developed and tested the technology, demonstrating its functionality and efficiency in controlled settings. Our accomplishment includes the design and development of a novel biosensor capable of detecting specific fungal infections, such as those caused by Candida and Aspergillus species. This biosensor integrates impedance measurement technology with AI algorithms for accurate identification.

Through rigorous testing and validation in laboratory settings, we have ensured the biosensor's accuracy and reliability in detecting fungal infections. Our testing phase involved simulated samples and controlled conditions to verify the biosensor's performance, showing high efficiency in detecting fungal infections with accuracy and speed.

While we have not yet publicly deployed the biosensor, our focus during the prototype stage has been on validating its functionality and performance. The intended beneficiaries of our solution include healthcare providers serving vulnerable populations, such as refugees and underserved communities in Turkey and beyond.

Our next steps will involve scaling up production and deployment to serve a broader population of healthcare providers and beneficiaries, ultimately improving access to timely and accurate diagnostics for fungal-related health issues.

We are applying to Solve because we believe in the profound impact of innovation on addressing global health challenges. Our vision aligns closely with Solve's mission to leverage technology for social good, particularly in improving access to quality diagnostics for fungal infections among underserved communities like refugees and vulnerable populations in Turkey and beyond.

Our team faces significant barriers that Solve can help us overcome. We are seeking support in refining our business model, achieving product-market fit, and developing scalable strategies. Solve's network can provide invaluable mentorship and resources to strengthen our approach.

Building a talented team and developing our board are crucial components of our success. Solve's connections can help us identify and attract the right talent and advisors who share our passion for global health equity.

Effective monitoring and evaluation are essential for measuring impact and refining our approach. Solve's expertise in data collection and impact measurement can enhance our ability to track and communicate progress.

Enhancing our branding and marketing strategy is vital for raising awareness and engagement around our solution. Solve can provide guidance on PR strategies and connections to media platforms to amplify our message.

As we continue to refine our biosensor technology, Solve's technical expertise can support software or hardware development, web design, and implementation.

Our goal in partnering with Solve extends beyond funding; it's about accessing a diverse network of partners and mentors who can provide the multidimensional support we need to accelerate our innovation's impact on global health. We are excited about the opportunity to collaborate with Solve's ecosystem to overcome these barriers and drive meaningful change in healthcare access worldwide.

Our solution is innovative because it combines advanced technology with a community-driven approach to address the pressing issue of equitable healthcare access. Unlike traditional methods of fungal infection diagnosis, which can be time-consuming, costly, and inaccessible to underserved populations, our solution leverages cutting-edge biosensor technology coupled with artificial intelligence.

The key innovation lies in our biosensor-based approach, specifically tailored for rapid and accurate detection of fungal infections. By integrating a gelatin-based hydrogel coating with impedance-based sensing, our biosensor can detect specific odor molecules emitted by fungal species associated with infections like Candida and Aspergillus. This method provides results within minutes, compared to the hours or days required by conventional laboratory cultures.

Our solution catalyzes broader positive impacts by democratizing access to timely and accurate diagnostics. By offering a portable, low-cost biosensor that can be deployed in diverse healthcare settings, including remote and resource-limited areas, we aim to empower healthcare providers and communities to detect and treat fungal infections promptly.

Furthermore, our approach has the potential to change the landscape of fungal infection diagnostics. By introducing a scalable and cost-effective solution, we anticipate a shift towards more proactive and efficient healthcare delivery. This could reduce the burden on healthcare systems and improve outcomes for vulnerable populations, ultimately paving the way for broader adoption of biosensor technology in infectious disease diagnostics.

In summary, our innovative solution bridges technology with community needs to revolutionize fungal infection diagnostics. By making diagnostics more accessible and efficient, we aim to catalyze positive impacts in healthcare delivery and inspire others in this space to leverage technology for equitable healthcare solutions.

Our solution, leveraging portable biosensors with gelatin-based hydrogel coatings and impedance-based sensing technology, aims to revolutionize fungal infection diagnostics, particularly for underserved populations.

The approach involves deploying these innovative biosensors to healthcare facilities and communities where access to timely and accurate diagnostics is limited. By analyzing odor molecules associated with fungal infections like Candida and Aspergillus, our biosensors can rapidly detect and diagnose these infections on-site, enabling immediate treatment initiation.

Through this approach, we expect to achieve several key impacts:

Firstly, our solution will facilitate timely diagnosis and treatment initiation, which can significantly reduce disease progression and associated complications, ultimately improving health outcomes for affected individuals.

Secondly, by improving access to diagnostic services in resource-limited and underserved areas, our solution contributes to enhancing healthcare equity, ensuring that vulnerable populations receive the care they urgently need.

Over the longer term, the widespread adoption of biosensor-based diagnostics can lead to a reduction in morbidity and mortality related to fungal infections, particularly among populations at high risk, such as refugees, low-income individuals, and those with compromised immune systems.

Our theory of change is supported by existing research demonstrating the effectiveness of biosensor technology in detecting specific odor molecules linked to fungal infections. Additionally, feedback from healthcare providers and community members underscores the critical need for accessible and rapid diagnostic tools in these settings.

In summary, our solution is poised to have a transformative impact by bridging the gap in fungal infection diagnostics, ultimately leading to improved health outcomes and greater healthcare equity for underserved populations globally.

Our impact goals for our solution are centered around achieving measurable improvements in healthcare outcomes and access for underserved populations affected by fungal infections. Specifically, we aim to:

1. Increase Timely Diagnosis Rates: Our goal is to ensure that a higher percentage of individuals with fungal infections, particularly in resource-limited settings and vulnerable communities, receive timely and accurate diagnoses. We aim to measure this progress by tracking the percentage of diagnosed cases within a specific timeframe after symptom onset.

2. Reduce Disease Complications: By enabling early detection and treatment initiation, we aim to reduce the incidence of severe complications associated with fungal infections, such as systemic infections or organ damage. We will measure this goal by tracking the rates of disease progression and related complications post-diagnosis.

3. Enhance Healthcare Equity: Our solution aims to contribute to greater healthcare equity by improving access to diagnostic services for marginalized and underserved populations. We will measure progress towards this goal by assessing the distribution of our biosensors in underserved areas and monitoring changes in access to diagnostics over time.

To measure our progress towards these impact goals, we will use specific indicators aligned with the UN Sustainable Development Goals (SDGs) related to health and well-being. These indicators may include:

• Percentage of individuals diagnosed within X days of symptom onset: This indicator will measure the timeliness of our diagnostic interventions.

• Reduction in severe complications associated with fungal infections: Tracking the incidence of complications post-diagnosis will help assess the effectiveness of our solution in preventing disease progression.

• Distribution of biosensors in underserved areas: We will monitor the geographical distribution of our biosensors to ensure equitable access across different communities and regions.

By consistently tracking these indicators and analyzing the data collected, we will be able to assess the impact of our solution on healthcare outcomes and access for vulnerable populations. This data-driven approach will guide our efforts to continuously optimize and refine our solution to maximize its transformative impact on people's lives.

Our solution leverages a combination of cutting-edge technologies—artificial intelligence (AI), big data analytics, and biotechnology/biomedical engineering—to revolutionize the detection and diagnosis of fungal infections, particularly for underserved populations.

The integration of AI plays a pivotal role in our solution by enabling advanced data analysis and pattern recognition. Our AI algorithms are designed to process vast amounts of molecular data extracted from patient samples, identifying specific genetic markers or protein signatures associated with different fungal species. By harnessing machine learning and deep learning techniques, our AI system continuously refines its diagnostic capabilities, achieving high accuracy and efficiency in fungal pathogen detection.

In parallel, our solution harnesses big data analytics to manage and analyze extensive datasets collected from diverse patient populations. This allows us to identify epidemiological trends, track disease outbreaks, and optimize treatment strategies based on real-time data insights. The utilization of big data empowers healthcare providers with actionable information, facilitating evidence-based decision-making and personalized patient care.

Furthermore, our solution integrates biotechnology and biomedical engineering through the development of innovative biosensor technologies. These biosensors are designed to detect specific fungal biomarkers in clinical samples rapidly and with high sensitivity. By combining biotechnology with AI-driven data analysis, our biosensors provide accurate and timely diagnostic results, enhancing the efficiency of fungal infection detection at the point of care.

The convergence of AI, big data, and biotechnology in our solution enables transformative impacts:

1. Enhanced Diagnostic Accuracy: AI-driven data analysis and biosensors deliver precise and reliable fungal infection diagnoses, reducing diagnostic errors and ensuring appropriate treatment interventions.

2. Real-time Surveillance and Monitoring: Leveraging big data analytics, our solution enables real-time disease surveillance and monitoring, supporting public health efforts to control and prevent fungal infections on a population level.

3. Accessibility and Scalability: The integration of innovative technologies makes our solution adaptable to diverse healthcare settings, including resource-limited areas and underserved communities where access to advanced diagnostic tools is limited.

4. Empowering Healthcare Providers: By automating complex diagnostic processes, our solution empowers frontline healthcare providers to deliver timely and effective care, ultimately improving patient outcomes and reducing healthcare disparities.

In summary, our interdisciplinary approach harnesses the strengths of AI, big data analytics, and biotechnology/biomedical engineering to address critical gaps in fungal infection diagnosis and management. Through innovation and technological integration, we aim to catalyze broader positive impacts in healthcare delivery and promote health equity for vulnerable populations worldwide.

We have currently 3 people in our team: The leader, The academic advisor, The researcher

Almost a year.

Our team is deeply committed to fostering diversity, equity, and inclusion (DEI) across all aspects of our work. We believe that diverse perspectives and backgrounds are essential for driving innovation and addressing complex challenges effectively.

Our team composition reflects a range of social, cultural, and identity-based attributes. We intentionally recruit team members from different backgrounds and experiences to bring unique insights to our work. For instance, our researcher is an immigrant woman from Morocco, bringing valuable perspectives on global health issues and cultural contexts. Our team leader, a young entrepreneur and STEM enthusiast, represents a new generation of leaders passionate about technology-driven solutions. Additionally, our academic advisor, as the first person in his family to attend college, offers a unique perspective on educational equity and access.

We actively minimize barriers to opportunity within our team by providing mentorship, skill development opportunities, and access to resources that support professional growth and advancement, particularly for individuals from underrepresented backgrounds. We prioritize creating an environment where everyone has equal access to opportunities for leadership and decision-making.

We strive to create a welcoming and inclusive environment where all team members feel valued, respected, and supported. This involves fostering open communication, actively listening to diverse viewpoints, and promoting a culture of collaboration and mutual respect. We encourage team members to contribute their unique perspectives and ideas, recognizing that inclusivity enhances creativity and problem-solving.

By embracing diversity, promoting equity, and fostering inclusion within our team, we aim to create a positive impact not only in our work but also in the broader communities we serve. Our commitment to DEI principles is fundamental to our mission and integral to driving meaningful change in global health and equity.